Furthermore, the same group has confirmed the safety and effectiveness of CD4 CAR-NK92 cells against various CD4+ T-cell lymphoma/leukemia cell lines and patient samples (95). Here, CD4 is linked to T-cell non-Hodgkin lymphoma.